Try our Advanced Search for more refined results

Vanda Pharmaceuticals Inc. v. Roxane Laboratories Inc.

  1. July 16, 2018

    Don't Rethink OK'ing Fanapt Patent, Vanda Tells Fed. Circ.

    Vanda Pharmaceuticals Inc. has asked the Federal Circuit not to reconsider West-Ward Pharmaceuticals' challenge to a patent covering the schizophrenia drug Fanapt, saying the court rightly found that the medication was patent-eligible under the U.S. Supreme Court's Mayo test.

  2. June 27, 2018

    Mylan Urges Full Fed. Circ. To Ax Vanda Drug IP Under Mayo

    Mylan Inc. urged the the full Federal Circuit to rehear a panel's split preservation of a patent covering Vanda Pharmaceuticals Inc.'s schizophrenia drug Fanapt, arguing Wednesday the patent claims don't meet the U.S. Supreme Court's Mayo standard for requiring a specific method of using natural phenomena for treatment.

  3. April 13, 2018

    Vanda Schizophrenia Drug Patentable, Fed. Circ. Says

    The Federal Circuit on Friday upheld a patent covering Vanda Pharmaceuticals Inc.'s schizophrenia drug Fanapt, finding it met the U.S. Supreme Court's Mayo standard by outlining a specific method of using natural phenomena for treatment.